Ontology highlight
ABSTRACT:
SUBMITTER: Polonio-Alcala E
PROVIDER: S-EPMC7281741 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature
Polonio-Alcalá Emma E Palomeras Sònia S Torres-Oteros Daniel D Relat Joana J Planas Marta M Feliu Lidia L Ciurana Joaquim J Ruiz-Martínez Santiago S Puig Teresa T
Cancers 20200519 5
Epidermal growth factor receptor (EGFR) tyrosine kinases inhibitors (TKIs) are effective therapies for non-small cell lung cancer (NSCLC) patients whose tumors harbor an EGFR activating mutation. However, this treatment is not curative due to primary and secondary resistance such as T790M mutation in exon 20. Recently, activation of transducer and activator of transcription 3 (STAT3) in NSCLC appeared as an alternative resistance mechanism allowing cancer cells to elude the EGFR signaling. Overe ...[more]